Small T N, Casson A, Malak S F, Boulad F, Kiehn T E, Stiles J, Ushay H M, Sepkowitz K A
Department of Pediatrics, Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Bone Marrow Transplant. 2002 Feb;29(4):321-7. doi: 10.1038/sj.bmt.1703365.
Respiratory syncytial virus, one of the most common causes of respiratory infections in immunocompetent individuals, is frequently spread to recipients of HSCT by family members, other patients, and health care workers. In immunosuppressed individuals, progression from upper respiratory tract disease to pneumonia is common, and usually fatal if left untreated. We performed a retrospective analysis of RSV infections in recipients of autologous or allogeneic transplants. The incidence of RSV following allogeneic or autologous HSCT was 5.7% and 1.5%, respectively. Of the 58 patients with an RSV infection, 16 of 21 patients identified within the first post-transplant month, developed pneumonia. Seventy-two percent of patients received aerosolized ribavirin and/or RSV-IGIV, including 23 of 25 patients diagnosed with RSV pneumonia. In this aggressively treated patient population, three patients died of RSV disease, each following an unrelated HSCT.
呼吸道合胞病毒是免疫功能正常个体呼吸道感染最常见的病因之一，常由家庭成员、其他患者及医护人员传播给造血干细胞移植（HSCT）受者。在免疫抑制个体中，从上呼吸道疾病进展为肺炎很常见，若不治疗通常会致命。我们对自体或异体移植受者的呼吸道合胞病毒感染进行了回顾性分析。异体或自体HSCT后呼吸道合胞病毒的发病率分别为5.7%和1.5%。在58例呼吸道合胞病毒感染患者中，移植后第一个月内确诊的21例患者中有16例发生了肺炎。72%的患者接受了雾化利巴韦林和/或呼吸道合胞病毒免疫球蛋白静脉注射（RSV-IGIV），其中25例诊断为呼吸道合胞病毒肺炎的患者中有23例接受了治疗。在这个积极治疗的患者群体中，3例患者死于呼吸道合胞病毒疾病，均在接受无关供者HSCT后发生。
